000			03323nam a22003855i 4500
001			84513
003			ES-MaUEC
005			20240611040139.0
007			cr nn 008mamaa
008			160901s2016 gw | s |||| 0|eng d
020			_a9783319015804
040			_aES-MaUEC
050		4	_aRC270 _b.D35 2016 EB
082	0	4	_a599.935
082	0	4	_a611.01816
100	1		_aDakubo, Gabriel D. _996747 _0Local _0http://id.loc.gov/authorities/names/n2010182687 _1http://viaf.org/viaf/120390581
245	1	0	_aCancer Biomarkers in Body Fluids : _bPrinciples _cby Gabriel D Dakubo
264		1	_aCham _bSpringer International Publishing _c2016
300			_a1 recurso en línea (XVI, 299 páginas) _b46 ilustraciones, 44 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
520			_aThe molecular and genetic signatures of cancer are represented in the peripheral circulation and other body fluids, giving rise to the zliquid biopsyy concept. This new paradigm of molecular profiling of cancer cells offers several advantages over traditional tissue biopsy. It is convenient, noninvasive, conforms to current clinical practice, enables real time disease monitoring and the study of tumor evolution, can easily be sampled multiple times, and this sample is more representative of the heterogeneous cancer cells than biopsy sampling. Indeed, all aspects of cancer molecular genetic information, stemming from DNA (both nuclear and mitochondria), RNA (coding and noncoding), peptides and proteins, metabolites and lipids are present in body fluids as free, cell surface bound or enclosed in membrane vesicles, and are being harnessed for disease management. Additionally, circulating tumor, and tumor stem cells provide prognostic information, and also enable the study of the intricate molecular processes associated with metastasis and drug resistance. This treatise deals with the general principles of the molecular pathology of cancer, and its associated imprints in circulation. The transitional process from discovery, prototype development, translational research, to product development can be complex and costly. The critical path to biomarker development and qualification for successful use in drug development is detailed herein as well. This book is of interest to Cancer Researchers, Oncologists, Clinicians, Surgeons, Medical Students, Nurses, Diagnostic Laboratories, and Pharmaceutical Industries.
650		7	_aCáncer _xInvestigación _2embne _9182523
650		7	_aGenética humana _2embne _9140562
710	2		_aSpringerLink (Online service) _0Local _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-01580-4 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9783319015804
907			_a.b12937915 _b10-10-17 _c21-11-16
942			_2lcc _cLE
945			_aEBOOK EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11612770 _z30-06-17
988	0	0	_aEBOOK, EBSPRINGER, GOBI_sep2018
988			_aEbook_one2one
998			_aSI _a_alco _a_vill _b10/2018 _cm _dz _ef _feng _ggw _h0
999			_c84513 _d84513 _x1